This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Colombo, E. Articles by Pelicci, P. G. Search for Related Content PubMed PubMed Citation Articles by Colombo, E. Articles by Pelicci, P. G.

Delocalization and Destabilization of the Arf Tumor Suppressor by the Leukemia-Associated NPM Mutant

¹ Department of Experimental Oncology and ² Division of Pathology, European Institute of Oncology; ³ IFOM Institute; and ⁴ Department of Medicine, Surgery, and Dentistry, University of Milan, Milan, Italy

Requests for reprints: Pier Giuseppe Pelicci, Department of Experimental Oncology, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy. Phone: 39-02-5748-9853; E-mail: piergiuseppe.pelicci{at}ifom-ieo-campus.it.

One third of acute myeloid leukemias (AMLs) are characterized by the aberrant cytoplasmic localization of nucleophosmin (NPM) due to mutations within its putative nucleolar localization signal. NPM mutations are mutually exclusive with major AML-associated chromosome rearrangements and are frequently associated with a normal karyotype, suggesting that they are critical during leukemogenesis. The underlying molecular mechanisms are, however, unknown. NPM is a nucleocytoplasmic shuttling protein that has been implicated in several cellular processes, including ribosome biogenesis, centrosome duplication, cell cycle progression, and stress response. It has been recently shown that NPM is required for the stabilization and proper nucleolar localization of the tumor suppressor p19^Arf. We report here that the AML-associated NPM mutant localizes mainly in the cytoplasm due to an alteration of its nucleus-cytoplasmic shuttling equilibrium, forms a direct complex with p19^Arf, but is unable to protect it from degradation. Consequently, cells or leukemic blasts expressing the NPM mutant have low levels of cytoplasmic Arf. Furthermore, we show that expression of the NPM mutant reduces the ability of Arf to initiate a p53 response and to induce cell cycle arrest. Inactivation of p19^Arf, a key regulator of the p53-dependent cellular response to oncogene expression, might therefore contribute to leukemogenesis in AMLs with mutated NPM. (Cancer Res 2006; 66(6): 3044-50)

This article has been cited by other articles:

				P. P. Di Fiore Playing both sides: nucleophosmin between tumor suppression and oncogenesis J. Cell Biol., July 14, 2008; 182(1): 7 - 9. [Abstract] [Full Text] [PDF]

				P. Bonetti, T. Davoli, C. Sironi, B. Amati, P. G. Pelicci, and E. Colombo Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7{gamma} J. Cell Biol., July 14, 2008; 182(1): 19 - 26. [Abstract] [Full Text] [PDF]

				O. Yogev, K. Saadon, S. Anzi, K. Inoue, and E. Shaulian DNA Damage-Dependent Translocation of B23 and p19ARF Is Regulated by the Jun N-Terminal Kinase Pathway Cancer Res., March 1, 2008; 68(5): 1398 - 1406. [Abstract] [Full Text] [PDF]

				N. Yoneda-Kato and J.-y. Kato Shuttling Imbalance of MLF1 Results in p53 Instability and Increases Susceptibility to Oncogenic Transformation Mol. Cell. Biol., January 1, 2008; 28(1): 422 - 434. [Abstract] [Full Text] [PDF]

				J. Li, D. P. Sejas, S. Burma, D. J. Chen, and Q. Pang Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability Carcinogenesis, June 1, 2007; 28(6): 1163 - 1170. [Abstract] [Full Text] [PDF]

				B. Falini, I. Nicoletti, N. Bolli, M. P. Martelli, A. Liso, P. Gorello, F. Mandelli, C. Mecucci, and M. F. Martelli Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias Haematologica, April 1, 2007; 92(4): 519 - 532. [Abstract] [Full Text] [PDF]

				B. Falini, I. Nicoletti, M. F. Martelli, and C. Mecucci Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features Blood, February 1, 2007; 109(3): 874 - 885. [Abstract] [Full Text] [PDF]

				C. Beekman, M. Nichane, S. De Clercq, M. Maetens, T. Floss, W. Wurst, E. Bellefroid, and J.-C. Marine Evolutionarily Conserved Role of Nucleostemin: Controlling Proliferation of Stem/Progenitor Cells during Early Vertebrate Development Mol. Cell. Biol., December 15, 2006; 26(24): 9291 - 9301. [Abstract] [Full Text] [PDF]

				L. Pasqualucci, A. Liso, M. P. Martelli, N. Bolli, R. Pacini, A. Tabarrini, M. Carini, B. Bigerna, A. Pucciarini, R. Mannucci, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification Blood, December 15, 2006; 108(13): 4146 - 4155. [Abstract] [Full Text] [PDF]